Biotech Tweet of the Week: Will Icahn Attack Gilead?

Gilead Sciences could follow in the footsteps of MedImmune (sold to AstraZeneca), Genzyme (sold to Sanofi), and ImClone (sold to Eli Lilly).

Brian Orelli
Brian Orelli
Apr 29, 2014 at 9:30AM
Health Care

This week, the tweet of the week comes from Paul DeSantis, who questions whether Carl Icahn might get involved with Gilead Sciences (NASDAQ:GILD) considering all the cash the biotech is expected to throw off over the next few years.

In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss why Icahn might want to become an activist investor in Gilead Sciences and whether that should scare investors. Considering his track record of getting companies sold -- MedImmune to AstraZeneca (NYSE:AZN), Genzyme to Sanofi, ImClone Systems to Eli Lilly (NYSE:LLY), just to name a few -- it can be an advantage to have Icahn on your side in the short term.

In the long run, it's an entirely different story.